Kornitzer Capital Management Inc. KS Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Kornitzer Capital Management Inc. KS lifted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 45.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 55,752 shares of the medical device company's stock after buying an additional 17,435 shares during the period. Kornitzer Capital Management Inc. KS's holdings in DexCom were worth $4,336,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter worth approximately $25,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the 4th quarter worth approximately $38,000. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the 3rd quarter worth approximately $57,000. Covestor Ltd grew its position in DexCom by 53.7% during the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after purchasing an additional 335 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its position in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after purchasing an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Price Performance

NASDAQ:DXCM traded down $0.56 during trading hours on Friday, reaching $88.78. 3,729,437 shares of the company were exchanged, compared to its average volume of 3,632,823. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock's 50-day moving average is $83.26 and its 200-day moving average is $75.94. The firm has a market cap of $34.69 billion, a PE ratio of 62.08, a price-to-earnings-growth ratio of 2.31 and a beta of 1.14. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Robert W. Baird raised shares of DexCom from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Raymond James dropped their price objective on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.06.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company's stock, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock worth $3,309,794 over the last three months. Insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.